Loading
A phase 2 trial of Ifinatamab deruxtecan in small-cell lung cancer, run by Daiichi Sankyo, active and no longer recruiting.
Ifinatamab Deruxtecan (I-DXd) in Subjects With Pretreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC) is a phase 2 interventional study registered as NCT05280470 by Daiichi Sankyo, with 187 participants enrolled, started 2022-03-09 and due to reach its primary completion in 2025-03-03. Interventions recorded: Ifinatamab Deruxtecan (I-DXd). Conditions listed: Extensive-stage Small-cell Lung Cancer. No results are recorded here; the registry entry is the source.
Shares Ifinatamab deruxtecan, Extensive-stage small-cell lung cancer, Antibody-drug conjugate (ADC), Small-cell lung cancer.
Shares Ifinatamab deruxtecan, Daiichi Sankyo, Extensive-stage small-cell lung cancer, Antibody-drug conjugate (ADC).
Shares Ifinatamab deruxtecan, Daiichi Sankyo, Antibody-drug conjugate (ADC).
Shares Ifinatamab deruxtecan, Daiichi Sankyo, Antibody-drug conjugate (ADC).
Shares Ifinatamab deruxtecan, Daiichi Sankyo, Antibody-drug conjugate (ADC).
Shares Ifinatamab deruxtecan, Extensive-stage small-cell lung cancer, Antibody-drug conjugate (ADC), Small-cell lung cancer.
Shares Ifinatamab deruxtecan, Daiichi Sankyo, Extensive-stage small-cell lung cancer, Antibody-drug conjugate (ADC).
Shares Ifinatamab deruxtecan, Daiichi Sankyo, Antibody-drug conjugate (ADC).